No title
The development of immunotherapeutic drugs has revolutionized cancer treatment and highlighted the immune system’s key role in combating cancer. Although immunotherapy has shown remarkable clinical benefits, treatment efficacy varies and low response rates are reported in several cancer types, including bladder cancer (BC). Although approved immune-checkpoint inhibitors (ICIs) have demonstrated lo
